Lukoll

Lukoll is a biotechnology company specializing in the discovery and development of targeted protein degradation (TPD) therapies, with a primary focus on molecular glues. Utilizing its proprietary Glue-T platform, the company aims to target "undruggable" proteins involved in oncology and immunological diseases. Lukoll integrates structural biology, computational chemistry, and high-throughput screening to accelerate the identification of novel small molecules that induce proximity between E3 ligases and disease-causing targets. The company is headquartered in Suzhou, China, and is positioned within the emerging field of induced proximity medicines.